Dr. Nowakowski on Next Steps With Emerging Agents in MCL

Grzegorz S. Nowakowski, MD
Published: Tuesday, May 16, 2017



Grzegorz S. Nowakowski, MD, an assistant professor of Medicine at Mayo Clinic, discusses the status of emerging agents moving through the pipeline of mantle cell lymphoma (MCL).

The agent that is closest to frontline therapy is the combination of lenalidomide (Revlimid) and rituximab (Rituxan), Nowakowski explains, which is also known as R-squared. This combination has been compared in a randomized study against chemoimmunotherapy with results that are now maturing. Another study demonstrated the benefit of maintenance therapy with rituximab in the post-induction setting for elderly patients, as well as following high-dose chemotherapy and autologous transplantation in young and fit patients.

Targeted therapies are being tested in the relapsed/refractory setting and are slowly moving to the upfront setting, he explains. Ibrutinib (Imbruvica) is one that has significant single-agent activity in MCL. The addition of ibrutinib is being studied with bendamustine and rituximab (BR) against BR alone in an ongoing phase III study.

Finally, venetoclax (Venclexta) was recently found to have significant single-agent activity in MCL. What is interesting, he says, is to see combinations of venetoclax and ibrutinib together in an effort to lose the chemotherapy backbone.


Grzegorz S. Nowakowski, MD, an assistant professor of Medicine at Mayo Clinic, discusses the status of emerging agents moving through the pipeline of mantle cell lymphoma (MCL).

The agent that is closest to frontline therapy is the combination of lenalidomide (Revlimid) and rituximab (Rituxan), Nowakowski explains, which is also known as R-squared. This combination has been compared in a randomized study against chemoimmunotherapy with results that are now maturing. Another study demonstrated the benefit of maintenance therapy with rituximab in the post-induction setting for elderly patients, as well as following high-dose chemotherapy and autologous transplantation in young and fit patients.

Targeted therapies are being tested in the relapsed/refractory setting and are slowly moving to the upfront setting, he explains. Ibrutinib (Imbruvica) is one that has significant single-agent activity in MCL. The addition of ibrutinib is being studied with bendamustine and rituximab (BR) against BR alone in an ongoing phase III study.

Finally, venetoclax (Venclexta) was recently found to have significant single-agent activity in MCL. What is interesting, he says, is to see combinations of venetoclax and ibrutinib together in an effort to lose the chemotherapy backbone.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x